The identification of five genes (KIF5C, LINC00632, B4GALNT3, HIF3A, and RAD51L3-RFFL) with differential expression between primary and recurrent tumors provides critical insight into the molecular mechanisms driving recurrence, the key challenge in the management of IDH wild-type glioma. This evidence concerns the gene HIF3A and central nervous system cancer.